Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04266730CT.gov Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab | — | Suspended | — | — | — |
NCT07221474CT.gov A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | — | Recruiting | — | — | — |
NCT05879484CT.gov Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | — | Withdrawn | — | — | — |
NCT07353957CT.gov Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05797168CT.gov Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | — | Recruiting | — | — | — |
NCT06307093CT.gov Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | — | Unknown | — | — | — |
NCT05566223CT.gov CISH Inactivated TILs in the Treatment of NSCLC | — | Withdrawn | — | — | — |
NCT04357873CT.gov Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations | — | Completed | — | — | — |
NCT04429542CT.gov Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Squamous Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | UNC Lineberger Comprehensive Cancer Center | P2 | BB · 65 |
| Cis-Diamminedichloroplatinum Ii | Qilu Hospital of Shandong University | P4 | BBB |
| Carboplatin | zhang yi | P3 | BBB |
| Docetaxel | Shanghai JMT-Bio Inc. | P3 | BBB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P3 | BB |
| Gefitinib | Seoul Veterans Hospital | P3 | BB |
| Etoposide | Barbara Ann Karmanos Cancer Institute | P3 | BB |
| Atezolizumab | Imugene Limited | P3 | BB |
| Veliparib | AbbVie | P3 | BB |
+42 more in the Squamous Cell Lung Carcinoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Squamous Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-squamous-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →